Our strong preliminary data demonstrate a novel therapeutic strategy for tumor therapy by engaging leukocyte complement receptor 3 (CR3, CD11b/CD18, alphaMbeta2-integrin) to kill tumor cells opsonized with iC3b. Therapeutic efficacy is achieved by using yeast beta-glucan in combination with anti-tumor mAbs in multiple mouse syngeneic tumor models. The long-term goal has been to understand the molecular and cellular mechanisms of action within yeast beta-glucan mediated tumor immunotherapy, and then promote it for clinical utilization with humanized anti-tumor mAbs or tumor vaccines eliciting a sufficient humoral response for activation of complement. We further demonstrate that yeast particulate beta-glucan stimulates dendritic cells for up-regulation of surface co-stimulatory molecules and MHC class II expression and secretion of IL-12 and TNF-alpha. Moreover, combined therapy of beta-glucan and MUC1 vaccine exhibits a synergistic effect on tumor regression. The central hypotheses to be tested in this proposal are: 1) yeast particulate beta-glucan enhances the adaptive immunity via secretion of cytokines and the enhanced dendritic cell antigen presentation; and 2) yeast beta-glucan has a synergistically therapeutic effect on a B cell-mediated MUC1 vaccine in MUC1/MT double Tg mice developing spontaneous mammary carcinoma.
Aim 1 determines whether beta-glucan mediated tumor immunotherapy promotes the adaptive T and B cell responses by using adoptively transferred OVA TCR transgenic OT-I (CDS) and/or OT-II T cells (CD4). The enhanced dendritic cell antigen presentation and subsequent enhanced antigen-specific T cell responses by beta-glucan will be determined.
Aim 2 uses a B cell-mediated MUC1 vaccine in combination with beta-glucan to investigate the therapeutic efficacy in MUC1/MT double Tg mice developing spontaneous mammary carcinoma. Targeting tumor-associated antigen MUC1 to B cells breaks T and B cell tolerance in MUC1 Tg mice. The enhancing effect of beta-glucan on anti-MUd T and B cell responses will be determined. Beta-glucan mediated immunotherapy demonstrates promising results in the therapeutic setting and is potentially remedial for cancer patients. ? ? ?
|Lane, Andrew N; Yan, Jun; Fan, Teresa W-M (2015) (13)C Tracer Studies of Metabolism in Mouse Tumor Xenografts. Bio Protoc 5:|
|Yan, Jun; Kloecker, Goetz; Fleming, Chris et al. (2014) Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells. Oncoimmunology 3:e950163|
|Albeituni, Sabrin Husein; Ding, Chuanlin; Yan, Jun (2013) Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J 19:490-501|
|Albeituni, Sabrin H; Yan, Jun (2013) The effects of ?-glucans on dendritic cells and implications for cancer therapy. Anticancer Agents Med Chem 13:689-98|
|Ma, Yunfeng; Xiang, Dong; Sun, Jinwen et al. (2013) Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J Immunol 190:5588-99|
|Gunn, Lacey; Ding, Chuanlin; Liu, Min et al. (2012) Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 189:2985-94|
|Xiang, D; Sharma, V R; Freter, C E et al. (2012) Anti-tumor monoclonal antibodies in conjunction with ?-glucans: a novel anti-cancer immunotherapy. Curr Med Chem 19:4298-305|
|Cai, Yihua; Shen, Xiaoyan; Ding, Chuanlin et al. (2011) Pivotal role of dermal IL-17-producing ?? T cells in skin inflammation. Immunity 35:596-610|
|Qi, Chunjian; Cai, Yihua; Gunn, Lacey et al. (2011) Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived ?-glucans. Blood 117:6825-36|
|Fan, Teresa W-M; Lane, Andrew N; Higashi, Richard M et al. (2011) Stable isotope resolved metabolomics of lung cancer in a SCID mouse model. Metabolomics 7:257-269|
Showing the most recent 10 out of 29 publications